Page 60 - ITPS-8-2

INNOSC Theranostics and
Pharmacological Sciences Management of heart failure in Pakistan

the soluble guanylate cyclase stimulator vericiguat (BAY 20. (PDF) Factors Associated with Congestive Heart Failure
1021189) for the treatment of chronic heart failure. J Med among Patients Presenting with Acute Cardiac Emergencies
Chem. 2017;60(12):5146-5161. in Northern Lahore. ResearchGate; 2024. Available from:
https://www.researchgate.net/publication/377306521_
doi: 10.1021/acs.jmedchem.7b00449
factors_associated_with_congestive_heart_failure_among_
10. Lombardi CM, Cimino G, Pagnesi M, et al. Vericiguat for patients_presenting_with_acute_cardiac_emergencies_in_
heart failure with reduced ejection fraction. Curr Cardiol northern_lahore [Last accessed on 2024 Dec 27].
Rep. 2021;23(10):144.
21. Bolam H, Morton G, Kalra PR. Drug therapies in chronic
doi: 10.1007/s11886-021-01580-6 heart failure: A focus on reduced ejection fraction. Clin Med
11. Hammer A, Niessner A, Sulzgruber P. Vericiguat: A fifth (Lond). 2018;18(2):138-145.
cornerstone in the treatment of heart failure with reduced doi: 10.7861/clinmedicine.18-2-138
ejection fraction? ESC Heart Failure. 2023;10(6):3735-3738.
22. Siddiqi AK, Greene SJ, Fudim M, Mentz RJ, Butler J,
doi: 10.1002/ehf2.14549 Khan MS. Vericiguat for the treatment of heart failure with
12. Nguyen NV, Lindberg F, Benson L, et al. Eligibility for reduced ejection fraction. Expert Rev Cardiovasc Ther.
vericiguat in a real‐world heart failure population according 2023;21(4):245-257.
to trial, guideline and label criteria: Data from the Swedish doi: 10.1080/14779072.2023.2189101
heart failure registry. Eur J Heart Fail. 2023;25(8):1418-
1428. 23. Ma J, Guo S, Jiang H, Li B. Efficacy and safety of
vericiguat in heart failure: A meta-analysis. J Int Med Res.
doi: 10.1002/ejhf.2939 2023;51(3):3000605231159333.
13. Seth S, Bauersachs J, Mittal S, et al. Expert opinion on doi: 10.1177/03000605231159333
the identification and pharmacological management of
worsening heart failure: A consensus statement from India. 24. Nakamura M, Imamura T, Kinugawa K. Initial experience
J Pract Cardiovasc Sci. 2023;9(1):1. of vericiguat treatment in patients with heart failure and
reduced ejection fraction. JCM. 2023;12(13):4396.
doi: 10.4103/jpcs.jpcs_32_23
doi: 10.3390/jcm12134396
14. Ilonze OJ, Guglin M. Vericiguat, organic nitrates, and heart
failure in African Americans. Int J Cardiol. 2021;338:136-137. 25. Aimo A, Castiglione V, Vergaro G, et al. The place of vericiguat
in the landscape of treatment for heart failure with reduced
doi: 10.1016/j.ijcard.2021.06.033 ejection fraction. Heart Fail Rev. 2022;27(4):1165-1171.
15. Khan MN, Soomro NA, Naseeb K, et al. Safety and tolerability doi: 10.1007/s10741-021-10146-1
of Sacubitril/Valsartan in heart failure patient with reduced
ejection fraction. BMC Cardiovasc Disord. 2023;23(1):133. 26. Merriel SWD, Andrews V, Salisbury C. Telehealth interventions
for primary prevention of cardiovascular disease: A systematic
doi: 10.1186/s12872-023-03070-9 review and meta-analysis. Prev Med. 2014;64:88-95.
16. Sahana U, Wehland M, Simonsen U, Schulz H, Grimm D. A doi: 10.1016/j.ypmed.2014.04.001
systematic review of the effect of vericiguat on patients with
heart failure. Int J Mol Sci. 2023;24(14):11826. 27. Alfieri M, Bruscoli F, Di Vito L, et al. Novel medical treatments
and devices for the management of heart failure with reduced
doi: 10.3390/ijms241411826 ejection fraction. J Cardiovasc Dev Dis. 2024;11(4):125.
17. Effectiveness of Self-Management Interventions on doi: 10.3390/jcdd11040125
Mortality, Hospital Readmissions, Chronic Heart Failure
Hospitalization Rate and Quality of Life in Patients with 28. Shaikh TG, Jawed S, Rahmat ZS, et al. Efficacy and safety of
Chronic Heart Failure: A Systematic Review. Available from: vericiguat for treatment of heart failure: A systematic review.
https://www.sciencedirect.com/science/article/abs/pii/ Curr Probl Cardiol. 2023;48(5):101586.
S073839911000025X [Last accessed on 2024 Dec 27]. doi: 10.1016/j.cpcardiol.2023.101586
18. Zafar R, Haris M, Assad S, et al. Core Measures for congestive 29. Jain SS, Li SS, Xie J, et al. Clinical and economic burden
heart failure in a tertiary care setting in Pakistan. Cureus. of obstructive hypertrophic cardiomyopathy in the United
2016;8:e728. States. J Med Econ. 2021;24(1):1115-1123.
doi: 10.7759/cureus.728 doi: 10.1080/13696998.2021.1978242
19. Husain MI, Chaudhry IB, Husain MO, et al. Depression and 30. Rashid AM, Khan MS, Fudim M, DeWald TA, DeVore A,
congestive heart failure: A large prospective cohort study Butler J. Management of heart failure with reduced ejection
from Pakistan. J Psychosom Res. 2019;120:46-52. fraction. Curr Problems Cardiol. 2023;48(5):101596.
doi: 10.1016/j.jpsychores.2019.03.008 doi: 10.1016/j.cpcardiol.2023.101596

Volume 8 Issue 2 (2025) 54 doi: 10.36922/itps.3756